Switch to fixed-dose doravirine/ islatravir (100/0.75 mg) once daily in adults with HIV-1 virologically suppressed on bictegravir/ emtricitabine/tenofovir alafenamide: Week 96 results of a phase 3, randomized, double-blind, non-inferiority trial